Herein, we evaluated EZH2 inhibitor GSK343, GCV and TMZ efficacy as single therapies, as well as bi- or tri-combination therapy on CEGBCs-DB, BL, and GBM spheroids (Fig. 8). The gene discussed is EZH2; the disease is glioblastoma.